Shockwave Medical Brand Guidelines: From Lithoplasty to a Johnson & Johnson MedTech Unit

A kidney-stone technique, moved into the arteries.

Shockwave Medical says it began in 2009, when “a marketer, engineer and cardiologist came together” around a single idea: that lithotripsy, the technique long used to break up kidney stones, could be adapted to crack calcium inside blood vessels. The company tells that story on its website under the heading “Chalk, Organic Eggs & Cadaver Legs,” and calls what began as “a crazy idea” the starting point for everything it now makes.

The first public record of the product comes from the U.S. Food and Drug Administration. Its 510(k) database lists a clearance dated 14 September 2016 for a “Lithoplasty Peripheral Balloon Dilatation Catheter,” with a matching generator and connector cable, filed by Shockwave from Fremont, California. Lithoplasty was the early product name. By June 2018 the FDA records the device as the Shockwave Medical Intravascular Lithotripsy (IVL) System, the name the company has used ever since, and a month later it lists the Shockwave M5 peripheral catheter. From August 2019 the filings give the company’s address as Santa Clara, where its head office remains.

The coronary version came next. The FDA’s premarket approval database shows a decision dated 12 February 2021 for the IVL System with the Shockwave C2 coronary catheter. Supplements followed for the C2+ in December 2022 and for a version called C2 Aero in October 2025. On the peripheral side the FDA lists clearances for the L6 catheter in 2022, the E8 in March 2024 and the Javelin in September 2024, followed in 2025 by the Shockwave CS guide catheter.

Sound waves, a balloon and a generator.

For Shockwave, the mechanism is the brand. In its April 2024 announcement, Johnson & Johnson described IVL as “a minimally invasive, catheter-based treatment for calcified arterial lesions” that works by “cracking calcium lesions using sonic pressure waves,” and said it is used in both coronary artery disease and peripheral artery disease, often together with stenting. Each FDA entry lists the same three parts: a lithotripsy catheter, a generator and a connector cable between them.

The product names stay short and technical. The coronary line is the C2, with the C2+ and C2 Aero after it; the peripheral catheters carry codes such as M5, S4, L6 and E8, with Javelin as the one worded name.

The voice around those names is playful. The website’s about page is titled “Same Shock, Bigger Waves,” its statistics sit under the heading “A Proven Crack Record,” and its contact prompt asks “Ready to make waves?” The same page sets out the figures the company leads with: it says it has launched 10 products since 2017, serves 70 countries and has treated more than one million patients with IVL. It also lists the honours it chooses to show, among them a 2023 Gold Edison Award for coronary IVL and places on Fast Company’s Most Innovative Companies list for 2022 and its Best Workplaces for Innovators list for 2023. Those are the company’s own figures and listings.

In 2024 Shockwave also reached beyond lithotripsy. Johnson & Johnson’s April 2024 release said Shockwave had recently acquired Neovasc, the developer of the Reducer System, which the release described as CE marked in the European Union and the United Kingdom and under clinical study in the United States. The Shockwave website labels the Reducer “Investigational Use Only” in the U.S. and Canada.

The FDA recall database records one Shockwave recall, of S4 peripheral catheters, begun in July 2018 over catheters that could not maintain inflation pressure; the FDA lists it as terminated.

Design and documentation.

Cardiovascular device makers sell to a narrow audience: interventional cardiologists, electrophysiologists, cardiac surgeons, hospital buyers and regulators. Their visual language follows from that. A heart valve, a stent or a pacemaker is small, precise and usually hidden inside the body once it is in use, so the product photograph does much of the work. Valves, stents and leads tend to be shot in close-up on white or pale grey, lit to show struts, mesh and metal edges, with the device itself as the only subject.

The second register is the catheterisation laboratory. Brochures, websites and congress stands return again and again to the same scene: a patient table, a C-arm X-ray system arched over it, banks of monitors showing angiograms or mapping images, and clinicians in scrubs, lead aprons and caps. These pictures place the device in the room where it is used, without showing the patient’s body in detail.

Between the two sits illustration. Cutaway hearts, cross-sections of arteries and simplified diagrams of the conduction system explain where a valve sits, how a stent opens or how a lead reaches the heart. They are often rendered in reds and soft pinks against white, with the brand’s own colour kept for the device, the arrows and the type. Much of the copy is technical, built around product names, trial names and regulatory approvals as the companies state them.

Much of the category’s public life happens at medical congresses. TCT in the United States, EuroPCR in Paris and the ESC Congress of the European Society of Cardiology bring makers, clinicians and trade press together each year, and companies use them to show new devices and announce study results. The makers in this guide range from family-owned German engineering firms to Chinese groups with several listed subsidiaries, and their identities reflect that range more than any shared house style.

Independent until May 2024, then part of Johnson & Johnson MedTech.

Shockwave Medical is no longer an independent company. Until 2024 it was listed on Nasdaq under the ticker SWAV. On 5 April 2024 Johnson & Johnson and Shockwave announced a definitive agreement under which Johnson & Johnson would buy all of Shockwave’s shares, a deal approved by both companies’ boards. The release placed it after Johnson & Johnson MedTech’s earlier purchases of Abiomed and of Laminar, a developer of left atrial appendage technology.

The acquisition was completed on 31 May 2024. Johnson & Johnson said that day that Shockwave “is now part of Johnson & Johnson” and would operate as a business unit within Johnson & Johnson MedTech, and that Shockwave’s stock had ceased trading on Nasdaq. It set the business beside its heart-recovery business, Abiomed, and its electrophysiology business, Biosense Webster.

The brand came through the sale intact. The website still carries the Shockwave Medical name, introduces its about page with the line “Now a part of Johnson & Johnson MedTech,” keeps a Santa Clara address and runs its own regional sites for Europe, Germany and Japan. Its copyright line still reads Shockwave Medical Inc., and the FDA continues to list new Shockwave catheters under the company’s own name, most recently in 2026.

For a design guide, Shockwave Medical shows how a single mechanism can carry a whole identity, from the product names to the wordplay on the website. Compare Abiomed, another Johnson & Johnson MedTech business, and Boston Scientific. For this guide we use a deep navy, a pulse cyan and a chalk white with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Shockwave Medical’s identity on hand — save it to a board in the Made Good inspiration library.